Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence.
Tumour necrosis factor (TNF), a key regulator of varied physiological mechanisms in multiple organ systems, is an immune signalling molecule produced by glia, neurons, macrophages and other immune cells. In the brain, among other functions, TNF serves as a gliotransmitter, secreted by glial cells that envelope and surround synapses, which regulates synaptic communication between neurons. The role of TNF as a gliotransmitter may help explain the profound synaptic effects of TNF that have been demonstrated in the hippocampus, in the spinal cord and in a variety of experimental models. Excess TNF is present in the CSF of individuals with Alzheimer's disease (AD), and has been implicated as a mediator of the synaptic dysfunction that is hypothesized to play a central role in the pathogenesis of AD. TNF may also play a role in endothelial and microvascular dysfunction in AD, and in amyloidogenesis and amyloid-induced memory dysfunction in AD. Genetic and epidemiological evidence has implicated increased TNF production as a risk factor for AD. Perispinal administration of etanercept, a potent anti-TNF fusion protein, produced sustained clinical improvement in a 6-month, open-label pilot study in patients with AD ranging from mild to severe. Subsequent case studies have documented rapid clinical improvement following perispinal etanercept in both AD and primary progressive aphasia, providing evidence of rapidly reversible, TNF-dependent, pathophysiological mechanisms in AD and related disorders. Perispinal etanercept for AD merits further study in randomized clinical trials.
Tobinick
Edward
E
Institute for Neurological Research, Los Angeles, California 90095, USA. etmd@ucla.edu
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D000818:Animals; D001921:Brain / Q000378:metabolism / Q000503:physiopathology; D016503:Drug Delivery Systems; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D009435:Synaptic Transmission; D014409:Tumor Necrosis Factor-alpha / Q000134:cerebrospinal fluid / Q000378:metabolism*
D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept
Neurology. 2007 May 29;68(22):1902-8
17536046
J Immunol. 1990 Apr 15;144(8):2999-3007
2109008
Am J Pathol. 2007 Jan;170(1):388-98
17200210
Mech Ageing Dev. 2006 Jun;127(6):567-71
16516271
Ital J Anat Embryol. 2006 Oct-Dec;111(4):221-46
17385278
Biochem Soc Trans. 2007 Nov;35(Pt 5):1219-23
17956317
J Neurochem. 2000 Feb;74(2):457-71
10646496
Neurology. 2001 Nov 27;57(10):1885-8
11723281
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
Arch Neurol. 2006 Aug;63(8):1165-9
16908746
Anat Rec. 1997 Oct;249(2):285-94
9335475
Nat Med. 2003 Oct;9(10):1245-50
14520364
FASEB J. 1999 Jan;13(1):63-8
9872930
Br J Clin Psychol. 2000 Jun;39(2):181-91
10895361
Am J Med Genet. 2002 Jul 8;114(5):574-7
12116197
Synapse. 2000 Feb;35(2):151-9
10611641
J Neurosci. 2006 Jan 4;26(1):246-55
16399694
Neurosci Lett. 1992 Nov 9;146(2):176-8
1337194
Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70
1103152
Arch Clin Neuropsychol. 2006 Aug;21(5):413-20
16843636
Science. 2002 Oct 25;298(5594):789-91
12399581
Arch Clin Neuropsychol. 2004 Aug;19(5):703-8
15330000
Clin Neuropsychol. 2004 Feb;18(1):122-31
15595364
Prog Neurobiol. 1999 Jun;58(3):233-47
10341362
Ann N Y Acad Sci. 2007 Feb;1097:40-50
17413008
Neurology. 1999 Aug 11;53(3):457-65
10449104
Nature. 2006 Apr 20;440(7087):1054-9
16547515
Am J Roentgenol Radium Ther Nucl Med. 1957 Aug;78(2):195-212
13444513
BMC Res Notes. 2009 Feb 27;2:28
19284700
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3410-5
16492745
Brain Res. 1989 Jul 10;491(2):394-7
2765895
Nat Rev Neurosci. 2005 Aug;6(8):626-40
16025096
J Neurosci Res. 2008 Oct;86(13):2867-75
18543334
Curr Med Res Opin. 2004 Jul;20(7):1075-85
15265252
Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):335-43
17493863
Bioorg Med Chem Lett. 2007 Jan 15;17(2):414-8
17079143
Neurobiol Aging. 2001 Nov-Dec;22(6):873-83
11754994
J Neurosci. 2007 May 16;27(20):5394-404
17507561
J Neurosci. 2001 Feb 15;21(4):1179-88
11160388
Trends Mol Med. 2005 Apr;11(4):170-6
15823755
J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5
12933918
Am J Pathol. 2008 Dec;173(6):1768-82
18974297
J Neurosci. 2005 Mar 23;25(12):3219-28
15788779
Ann Surg. 1940 Jul;112(1):138-49
17857618
Pharmacol Ther. 2008 Feb;117(2):244-79
18155297
MedGenMed. 2006 Apr 26;8(2):25
16926764
Drug Discov Today. 2009 Feb;14(3-4):168-77
19027875
Neuron. 2004 Sep 30;44(1):181-93
15450169
J Neurosci. 2006 Jan 11;26(2):662-70
16407564
Trends Neurosci. 2007 Aug;30(8):417-24
17631972
J Rheumatol. 2007 Jan;34(1):239-40; discussion 240
17216704
MedGenMed. 2006 Feb 22;8(1):53
16915183
Brain Behav Immun. 2007 Mar;21(3):281-9
17275255
Arch Neurol. 1994 Jan;51(1):41-5
8274108
Behav Brain Res. 2008 May 16;189(1):100-6
18325608
Biochem Biophys Res Commun. 1991 Dec 31;181(3):1532-8
1662500
Trends Mol Med. 2008 Mar;14(3):103-8
18262842
J Clin Immunol. 1999 Jul;19(4):223-30
10471976
Nat Neurosci. 2006 Feb;9(2):260-7
16388306
J Neurosci. 2005 Mar 16;25(11):2952-64
15772355
J Cell Biol. 2007 Aug 27;178(5):829-41
17724122
J Neuroinflammation. 2008 Jan 09;5:2
18184433
Clin Ther. 2003 Aug;25(8):2279-88
14512134
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6828-33
17420446
Nature. 1998 Feb 26;391(6670):892-6
9495341
J R Soc Interface. 2009 Aug 6;6(37):655-68
18986963
Exp Physiol. 2005 Sep;90(5):663-70
15944202
Eur J Pharmacol. 2006 Sep 1;545(1):11-21
16887118
Alzheimer Dis Assoc Disord. 2001 Oct-Dec;15(4):174-83
11723368
Neurobiol Dis. 2005 Jun-Jul;19(1-2):129-41
15837568
Neurobiol Aging. 2001 Jul-Aug;22(4):671-6
11445267
Clin Neuropsychol. 2007 Jul;21(4):587-616
17613980
J Am Geriatr Soc. 2005 Apr;53(4):695-9
15817019
Eur Neurol. 2008;59(1-2):91-3
17934280
NeuroRx. 2005 Jan;2(1):3-14
15717053
J Neural Transm (Vienna). 2006 Nov;113(11):1709-15
16736247
Brain Res. 2005 Aug 16;1053(1-2):54-61
16040010
Curr Alzheimer Res. 2004 Feb;1(1):27-32
15975082
Neuropsychology. 1998 Apr;12(2):259-67
9556772
Glia. 2007 Sep;55(12):1214-21
17659528
PLoS One. 2008;3(11):e3604
18978948
Neurology. 1996 Dec;47(6):1531-4
8960740
Int J Geriatr Psychiatry. 2004 Jan;19(1):41-50
14716698
Proc Natl Acad Sci U S A. 1989 Oct;86(19):7611-5
2529544
BMC Neurol. 2008 Jul 21;8:27
18644112
Neurology. 1984 Jul;34(7):939-44
6610841
Brain Res. 2005 Feb 9;1034(1-2):11-24
15713255
Nat Neurosci. 2003 Jan;6(1):43-50
12469126
Curr Alzheimer Res. 2007 Dec;4(5):550-2
18220520
Trends Mol Med. 2007 Feb;13(2):54-63
17207662
Ann Rheum Dis. 2009 Mar;68(3):362-6
18390569
J Neurosci. 2005 Mar 9;25(10):2566-75
15758166
Appl Neuropsychol. 1999;6(4):247-51
10635440
Science. 2002 Mar 22;295(5563):2282-5
11910117
Anesth Analg. 2006 Mar;102(3):973-4
16492873
FASEB J. 2006 Mar;20(3):494-6
16423877
Spine (Phila Pa 1976). 2004 Jul 1;29(13):1465-71
15223940
J Neurosurg. 1997 Feb;86(2):252-62
9010427
Swiss Med Wkly. 2003 Mar 22;133(11-12):170-7
12715286
Neuroimmunomodulation. 1995 May-Jun;2(3):161-5
8646566
Ann Neurol. 1980 May;7(5):486-8
7396427
Medscape J Med. 2008 Jun 10;10(6):135
18679537
Hum Mutat. 2005 Jul;26(1):29-35
15895461
Am J Pathol. 2007 Feb;170(2):680-92
17255335
Prog Neurobiol. 2000 Feb;60(2):109-37
10639051
Neuron. 2007 Feb 1;53(3):337-51
17270732
Eur J Neurosci. 2005 Dec;22(11):2827-32
16324117
Pharm Res. 2005 Jul;22(7):1011-37
16028003
J Neurosurg. 1951 Jul;8(4):411-22
14851015
Clin Neuropsychol. 2008 May;22(3):507-18
17853128